420 related articles for article (PubMed ID: 36797612)
1. The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington's Disease.
Bhat SA; Ahamad S; Dar NJ; Siddique YH; Nazir A
Curr Neuropharmacol; 2023; 21(4):867-889. PubMed ID: 36797612
[TBL] [Abstract][Full Text] [Related]
2. Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
Essa MM; Moghadas M; Ba-Omar T; Walid Qoronfleh M; Guillemin GJ; Manivasagam T; Justin-Thenmozhi A; Ray B; Bhat A; Chidambaram SB; Fernandes AJ; Song BJ; Akbar M
Neurotox Res; 2019 Apr; 35(3):739-774. PubMed ID: 30632085
[TBL] [Abstract][Full Text] [Related]
3. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
4. Huntington's Disease and Mitochondria.
Jodeiri Farshbaf M; Ghaedi K
Neurotox Res; 2017 Oct; 32(3):518-529. PubMed ID: 28639241
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective Effects of σ
Jin J; Arbez N; Sahn JJ; Lu Y; Linkens KT; Hodges TR; Tang A; Wiseman R; Martin SF; Ross CA
ACS Chem Neurosci; 2022 Oct; 13(19):2852-2862. PubMed ID: 36108101
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.
Sawant N; Morton H; Kshirsagar S; Reddy AP; Reddy PH
Mol Neurobiol; 2021 Dec; 58(12):6350-6377. PubMed ID: 34519969
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.
Ahamad S; Bhat SA
J Med Chem; 2022 Dec; 65(24):15993-16032. PubMed ID: 36490325
[TBL] [Abstract][Full Text] [Related]
8. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants for neuroprotection in Huntington's disease: A review.
Jamwal S; Kumar P
Eur J Pharmacol; 2015 Dec; 769():33-42. PubMed ID: 26511378
[TBL] [Abstract][Full Text] [Related]
10. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
Dean M; Sung VW
Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
12. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.
Tobore TO
J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621
[TBL] [Abstract][Full Text] [Related]
13. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial and Redox-Based Therapeutic Strategies in Huntington's Disease.
Fão L; Rego AC
Antioxid Redox Signal; 2021 Mar; 34(8):650-673. PubMed ID: 32498555
[No Abstract] [Full Text] [Related]
15. Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics.
Naia L; Carmo C; Campesan S; Fão L; Cotton VE; Valero J; Lopes C; Rosenstock TR; Giorgini F; Rego AC
Free Radic Biol Med; 2021 Feb; 163():163-179. PubMed ID: 33285261
[TBL] [Abstract][Full Text] [Related]
16. Deutetrabenazine for the treatment of Huntington's chorea.
Bashir H; Jankovic J
Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
[TBL] [Abstract][Full Text] [Related]
17. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dynamics and quality control in Huntington's disease.
Guedes-Dias P; Pinho BR; Soares TR; de Proença J; Duchen MR; Oliveira JM
Neurobiol Dis; 2016 Jun; 90():51-7. PubMed ID: 26388396
[TBL] [Abstract][Full Text] [Related]
19. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
20. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
